BioAtla to Present Breakthrough Cancer Treatment Research Soon
BioAtla Announces Upcoming Poster Presentation at ASCO Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a pioneering global biotechnology firm engaged in the development of Conditionally Active Biologic (CAB) antibody therapeutics for treating solid tumors, recently revealed plans for a poster presentation at the noteworthy American Society of Clinical Oncology (ASCO) Annual Meeting. The event is scheduled to take place online and at the renowned McCormick Place Convention Center, with activities expected to run from May 30 to June 3.
Details of the Presentation
This presentation will introduce innovative findings from BioAtla’s Phase 2 clinical trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-targeted antibody-drug conjugate designed specifically for patients suffering from heavily pretreated squamous cell carcinoma of the head and neck.
Highly Anticipated Points
Title of Presentation: Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.
Abstract Number: 6048
Session Type: Poster #456
Session Title: Head and Neck Cancer
Session Date and Time: Monday, June 2; 9:00 AM – 12:00 PM CDT
Innovative CAB Technology and Company Overview
BioAtla has positioned itself at the forefront of biotechnology through its innovative CAB platform technology. This proprietary approach enables the development of monoclonal and bispecific antibodies that are distinct in their ability to selectively target cancer cells. As a clinical-stage organization, BioAtla is dedicated to addressing the unmet medical needs of patients with various malignancies. The focus remains on delivering therapies with enhanced efficacy and reduced toxicity, providing a more promising alternative to conventional treatment methods.
Current Development Pipeline
Among BioAtla's promising pipeline is BA3182, the first dual CAB bispecific T-cell engager antibody currently in Phase 1 trials. This groundbreaking product is engineered to target EpCAM, a protein frequently expressed in adenocarcinomas while effectively engaging human CD3-expressing T cells to enhance immune responses against tumors.
The company is also actively advancing two leading CAB programs in Phase 2 testing: mecbotamab vedotin, a conditionally active AXL-targeted antibody-drug conjugate, and ozuriftamab vedotin, which targets ROR2. Moreover, the Phase 2 CAB-CTLA-4 antibody, evalstotug, functions as a novel inhibitor designed to minimize systemic toxicity and potentially enable safer combinations with checkpoint inhibitors.
Company Growth and Future Directions
BioAtla's extensive patent portfolio comprises over 780 active patent matters, ensuring robust protection for its innovative technologies across major global markets. This strategic focus on intellectual property enables BioAtla to maintain a competitive edge and supports its commitment to advancing scientific breakthroughs in oncology.
As the ASCO Annual Meeting approaches, the excitement surrounding BioAtla’s contributions to cancer treatment continues to grow. The company’s dedication to patient care and scientific innovation positions it as a leader in the biotechnology landscape, and it looks forward to sharing these pivotal insights with the wider medical community.
Internal and External Contacts
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
Email: rwaldron@bioatla.com
Phone: 858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
Email: bmackle@lifesciadvisors.com
Frequently Asked Questions
What is BioAtla, Inc. known for?
BioAtla is a biotechnology firm focused on developing innovative CAB antibody therapies for oncology and other medical needs.
What recent event is BioAtla participating in?
BioAtla will present at the ASCO Annual Meeting, showcasing findings from their clinical trials.
What is ozuriftamab vedotin?
Ozuriftamab vedotin (BA3021) is a conditionally active antibody-drug conjugate targeting ROR2 for treating advanced squamous cell carcinoma.
How does BioAtla's CAB technology work?
The CAB technology enables the creation of antibodies that are designed to selectively bind to cancer cells, optimizing treatment effectiveness and reducing side effects.
How can I contact BioAtla for more information?
For inquiries, you can reach Richard Waldron, CFO, at rwaldron@bioatla.com or call 858.356.8945.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.